https://orcid.org/0000-0002-3231-3357
References
- Cummings SR, Cosman F, Lewiecki EM, et al. Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis. J Bone Miner Res. 2017 Jan;32(1):3–10. .
- Bouxsein ML, Eastell R, Lui LY, et al. Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res. 2019 Apr;34(4):632–642. .
- Bauer DC, Schwartz A, Palermo L, et al. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med. 2014 Jul;174(7):1126–1134. .
- Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011 Apr;96(4):972–980. .
- Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018 Feb;33(2):190–198. .
- Anastasilakis AD, Yavropoulou MP, Makras P, et al. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur J Endocrinol. 2017 Jun;176(6):677–683. .
- Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone. 2017 Dec;105:11–17.
- Ferrari S, Libanati C, Cjf L, et al. Relationship between bone mineral densityT-score and nonvertebral fracture risk over 10 years of denosumab treatment. J Bone Miner Res. 2019 Mar 28;34:1033–1040. .
- Anastasilakis AD, Papapoulos SE, Polyzos SA, et al. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. a prospective 2-year clinical trial. J Bone Miner Res. 2019 Dec;34(12):2220–2228.
- Solling AS, Harslof T, Langdahl B. Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J Bone Miner Res. 2020May27;35(10):1858–1870.
- Tripto-Shkolnik L, Fund N, Rouach V, et al. Fracture incidence after denosumab discontinuation: real-world data from a large health care provider. Bone. 2020 Jan;130:115150.
- Lyu H, Yoshida K, Zhao SS, et al. Delayed denosumab injections and fracture risk among patients with osteoporosis: a population-based cohort study. Ann Intern Med. 2020 Jul 28;173(7):516–526.
- Brown JP, Roux C, Torring O, et al. Discontinuation of denosumab and associated fracture incidence: analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM) trial. J Bone Miner Res. 2013 Apr;28(4):746–752. .
- McClung MR, Wagman RB, Miller PD, et al. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int. 2017 May;28(5):1723–1732. .
- Kendler D, Chines A, Clark P, et al. Bone mineral density after transitioning from denosumab to alendronate. J Clin Endocrinol Metab. 2020 Mar 1;105(3):e255-e264.
- Makras P, Papapoulos SE, Polyzos SA, et al. The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. Bone. 2020 Sep;138:115478.
- Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020 Oct 26. 10.1210/clinem/dgaa756.